Alembic Pharma shares soar 14% on USFDA approval for cancer drug; check details

Drugmaker Alembic Pharma’s share soared as much as 14% on Monday, June 30, after the company received final approval from the US FDA for its ovarian cancer drug.

Doxorubicin Hydrochloride Liposome Injection will be used for the treatment of Ovarian Cancer, AIDS-Related Kaposi’s Sarcoma, and Multiple Myeloma.

According to IQVIA, Doxorubicin Hydrochloride Liposome Injection, 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) single-dose vials have an estimated market size of $29 million for twelve months ending March 2025.

Alembic has a cumulative total of 224 ANDA approvals (201 final approvals and 23 tentative approvals) from the USFDA.

Last seen, shares of Alembic Pharma were trading at ₹1,101.80 apiece, soaring 13.72% on the National Stock Exchange.

For the January-March quarter, Alembic Pharmaceuticals witnessed a mixed set of numbers, with a drop in profit despite healthy top-line growth. The company’s consolidated net profit declined 11.8% year-on-year (YoY) to ₹157 crore, compared to ₹178 crore in the same quarter last year.

However, its revenue climbed 16.7% to ₹1,769.6 crore in Q4 FY25 from ₹1,517 crore in Q4 FY24.

Operating performance remained steady, with earnings before interest, taxes, depreciation, and amortisation (EBITDA) increasing 4.6% to ₹272 crore against ₹260 crore in the year-ago period. The margin, however, slipped to 15.4% from 17.1% a year earlier.

After opening at ₹989 per share on Monday, Alembic Pharma stock touched an intraday high of ₹1,107.90 apiece, surging over 14% from its previous close.

Over the last five trading days, shares of the pharma major have soared almost 17%. For a month’s period, it has increased over 10%.

Since December 31, 2024, which is six months, the stock has climbed 3%. Year-to-date, it has increased 5%.

The company’s market capitalisation stands at ₹21,445.04 crore.

Shares of the firm had touched its one-year high of ₹1,303.90 apiece on October 6, 2024, while its 52-week low of ₹725.20 was hit on March 3, 2025.